跳至主要内容
临床试验/CTRI/2023/12/060945
CTRI/2023/12/060945尚未招募3 期

Safety and efficacy of combination of thalidomide and hydroxyurea in children with transfusion dependent thalassemia: A phase III, multicentric, double-blind randomized placebo-controlled trial. - NI

ICMR, Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a.Children aged 2-18 years.
  • b.Diagnosis of transfusion dependent thalassemia, requiring regular blood transfusions.
  • c.Willing for regular follow up as required for the study
  • d.Informed consent given
  • e.Patients with child bearing potential must be willing for contraception (wherever applicable)

排除标准

  • a.Patients with hypersplenism and planning splenectomy during the next year
  • b.Patients planning for hematopoietic stem cell transplantation (HSCT)
  • c.Retroviral infection
  • d.Chronic active hepatitis (Hepatitis B or Hepatitis C)
  • e.Elevation of transaminases more than 5 times of upper limit of normal
  • f.Renal failure
  • g.Symptomatic cardiac failure and LVEF < 50%
  • h.Past history of stroke
  • i.Received hydroxyurea, thalidomide or luspatercept in the previous 6 months
  • j.Pregnancy or lactation

研究者

发起方
ICMR, Delhi

相似试验

se of medicines- Hydroxyurea and thalidomide for... | 临床试验